P. Jansen, G. Lodde, A. Zaremba, C. M. Thielmann, Johanna Matull, H. Müller, Inga Möller, A. Sucker, S. Esser, J. Schaller, D. Schadendorf, T. Mentzel, E. Hadaschik, K. Griewank
{"title":"良恶性皮肤血管肿瘤中罕见的TERT启动子突变","authors":"P. Jansen, G. Lodde, A. Zaremba, C. M. Thielmann, Johanna Matull, H. Müller, Inga Möller, A. Sucker, S. Esser, J. Schaller, D. Schadendorf, T. Mentzel, E. Hadaschik, K. Griewank","doi":"10.3390/dermato1010003","DOIUrl":null,"url":null,"abstract":"Mutations in the promoter of the telomerase reverse transcriptase (TERT) gene have been described as the most common hot-spot mutations in different solid tumors. High frequencies of TERT promoter mutations have been reported to occur in tumors arising in tissues with low rates of self-renewal. For cutaneous vascular tumors, the prevalence of TERT promoter mutations has not yet been investigated in larger mixed cohorts. With targeted next-generation sequencing (NGS), we screened for different known recurrent TERT promoter mutations in various cutaneous vascular proliferations. In our cohort of 104 representative cutaneous vascular proliferations, we identified 7 TERT promoter mutations. We could show that 4 of 64 (6.3%) hemangiomas and vascular malformations harbored TERT promoter mutations (1 Chr.5:1295228 C > T mutations, 1 Chr.5:1295228_9 CC > TT mutation, and 2 Chr.5:1295250 C > T mutations), 1 of 19 (5.3%) angiosarcomas harbored a Chr.5:1295250 C > T TERT promoter mutation, and 2 of 21 (9.5%) Kaposi’s sarcomas harbored TERT promoter mutations (2 Chr.5:1295250 C > T mutations). To our knowledge, this is the first general description of the distribution of TERT promoter mutations in a mixed cohort of cutaneous vascular tumors, revealing that TERT promoter mutations seem to occur with low prevalence in both benign and malignant cutaneous vascular proliferations.","PeriodicalId":11115,"journal":{"name":"Dermato-Endocrinology","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rare TERT Promoter Mutations Present in Benign and Malignant Cutaneous Vascular Tumors\",\"authors\":\"P. Jansen, G. Lodde, A. Zaremba, C. M. Thielmann, Johanna Matull, H. Müller, Inga Möller, A. Sucker, S. Esser, J. Schaller, D. Schadendorf, T. Mentzel, E. Hadaschik, K. Griewank\",\"doi\":\"10.3390/dermato1010003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mutations in the promoter of the telomerase reverse transcriptase (TERT) gene have been described as the most common hot-spot mutations in different solid tumors. High frequencies of TERT promoter mutations have been reported to occur in tumors arising in tissues with low rates of self-renewal. For cutaneous vascular tumors, the prevalence of TERT promoter mutations has not yet been investigated in larger mixed cohorts. With targeted next-generation sequencing (NGS), we screened for different known recurrent TERT promoter mutations in various cutaneous vascular proliferations. In our cohort of 104 representative cutaneous vascular proliferations, we identified 7 TERT promoter mutations. We could show that 4 of 64 (6.3%) hemangiomas and vascular malformations harbored TERT promoter mutations (1 Chr.5:1295228 C > T mutations, 1 Chr.5:1295228_9 CC > TT mutation, and 2 Chr.5:1295250 C > T mutations), 1 of 19 (5.3%) angiosarcomas harbored a Chr.5:1295250 C > T TERT promoter mutation, and 2 of 21 (9.5%) Kaposi’s sarcomas harbored TERT promoter mutations (2 Chr.5:1295250 C > T mutations). To our knowledge, this is the first general description of the distribution of TERT promoter mutations in a mixed cohort of cutaneous vascular tumors, revealing that TERT promoter mutations seem to occur with low prevalence in both benign and malignant cutaneous vascular proliferations.\",\"PeriodicalId\":11115,\"journal\":{\"name\":\"Dermato-Endocrinology\",\"volume\":\"17 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermato-Endocrinology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/dermato1010003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermato-Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/dermato1010003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
端粒酶逆转录酶(TERT)基因启动子的突变已被描述为不同实体肿瘤中最常见的热点突变。据报道,TERT启动子突变的高频率发生在自我更新率低的组织中产生的肿瘤中。对于皮肤血管肿瘤,TERT启动子突变的患病率尚未在更大的混合队列中进行研究。通过靶向下一代测序(NGS),我们筛选了各种皮肤血管增生中不同已知的复发性TERT启动子突变。在我们的104例具有代表性的皮肤血管增生队列中,我们确定了7个TERT启动子突变。我们发现64例血管瘤和血管畸形中有4例(6.3%)存在TERT启动子突变(1例chr5:1295228 C > T突变,1例chr5:1295228_9 CC > TT突变,2例chr5: 1295250c > T突变),19例血管肉瘤中有1例(5.3%)存在TERT启动子突变(2例chr5: 1295250c > T突变),21例卡波西氏肉瘤中有2例(9.5%)存在TERT启动子突变(2例chr5: 1295250c > T突变)。据我们所知,这是首次对TERT启动子突变在皮肤血管肿瘤混合队列中的分布进行一般性描述,揭示了TERT启动子突变在良性和恶性皮肤血管增生中的发生率似乎都很低。
Rare TERT Promoter Mutations Present in Benign and Malignant Cutaneous Vascular Tumors
Mutations in the promoter of the telomerase reverse transcriptase (TERT) gene have been described as the most common hot-spot mutations in different solid tumors. High frequencies of TERT promoter mutations have been reported to occur in tumors arising in tissues with low rates of self-renewal. For cutaneous vascular tumors, the prevalence of TERT promoter mutations has not yet been investigated in larger mixed cohorts. With targeted next-generation sequencing (NGS), we screened for different known recurrent TERT promoter mutations in various cutaneous vascular proliferations. In our cohort of 104 representative cutaneous vascular proliferations, we identified 7 TERT promoter mutations. We could show that 4 of 64 (6.3%) hemangiomas and vascular malformations harbored TERT promoter mutations (1 Chr.5:1295228 C > T mutations, 1 Chr.5:1295228_9 CC > TT mutation, and 2 Chr.5:1295250 C > T mutations), 1 of 19 (5.3%) angiosarcomas harbored a Chr.5:1295250 C > T TERT promoter mutation, and 2 of 21 (9.5%) Kaposi’s sarcomas harbored TERT promoter mutations (2 Chr.5:1295250 C > T mutations). To our knowledge, this is the first general description of the distribution of TERT promoter mutations in a mixed cohort of cutaneous vascular tumors, revealing that TERT promoter mutations seem to occur with low prevalence in both benign and malignant cutaneous vascular proliferations.